These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20469618)

  • 21. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF; Timmer W; Sagkriotis A; Viel K
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P
    MMW Fortschr Med; 2003 Jun; 145(24):20. PubMed ID: 12866294
    [No Abstract]   [Full Text] [Related]  

  • 24. [Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease].
    Vestbo J
    Ugeskr Laeger; 2004 Jan; 166(4):271-4. PubMed ID: 14964108
    [No Abstract]   [Full Text] [Related]  

  • 25. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
    BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma.
    Currie GP; Syme-Grant NJ; McFarlane LC; Carey FA; Lipworth BJ
    Allergy; 2003 Jul; 58(7):602-7. PubMed ID: 12823118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease.
    Lyseng-Williamson KA; Keating GM
    Am J Respir Med; 2002; 1(4):273-82; discussion 283-4. PubMed ID: 14720047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ; Cates CJ; Poole P
    Cochrane Database Syst Rev; 2010 May; (5):CD007891. PubMed ID: 20464758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov; 145(46):47. PubMed ID: 14699834
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical therapy for COPD: lessons from the real world.
    Calverley PM
    Eur Respir J; 2002 Oct; 20(4):797-8. PubMed ID: 12412666
    [No Abstract]   [Full Text] [Related]  

  • 32. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
    Aubier M; Pieters WR; Schlösser NJ; Steinmetz KO
    Respir Med; 1999 Dec; 93(12):876-84. PubMed ID: 10653049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Inhalation of beta-2 agonists or corticosteroids as single drugs in comparison with combination therapy of patients with COPD].
    Steurer-Stey C
    Praxis (Bern 1994); 2003 Jul; 92(31-32):1324-5. PubMed ID: 12934343
    [No Abstract]   [Full Text] [Related]  

  • 34. Stepping down therapy in COPD.
    Reilly JJ
    N Engl J Med; 2014 Oct; 371(14):1340-1. PubMed ID: 25196116
    [No Abstract]   [Full Text] [Related]  

  • 35. Differentiating asthma and COPD patients.
    El-Kassimi FA
    Chest; 2004 Aug; 126(2):653-4; author reply 654-5. PubMed ID: 15302761
    [No Abstract]   [Full Text] [Related]  

  • 36. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.
    Halpin DM; Gray J; Edwards SJ; Morais J; Singh D
    Int J Clin Pract; 2011 Jul; 65(7):764-74. PubMed ID: 21676119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD.
    Maltais F; Mahler DA; Pepin V; Nadreau E; Crater GD; Morris AN; Emmett AH; Ferro TJ
    Eur Respir J; 2013 Aug; 42(2):539-41. PubMed ID: 23904549
    [No Abstract]   [Full Text] [Related]  

  • 39. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.
    Soriano JB; Vestbo J; Pride NB; Kiri V; Maden C; Maier WC
    Eur Respir J; 2002 Oct; 20(4):819-25. PubMed ID: 12412670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic obstructive pulmonary disease megatrials: taking the results into office practice.
    Stoloff SW
    Am J Med Sci; 2011 Aug; 342(2):160-7. PubMed ID: 21512392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.